Lineage Cell Therapeutics Inc. — Director's Dealing 2016

Mar 3, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Asterias Biotherapeutics, Inc. (AST)
CIK: 0001572552
Period of Report: 2016-02-29

Reporting Person: BIOTIME INC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-02-29	Series A Common Stock	J	75771	—	Disposed	21747569	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-29	Warrants to purchase Series A Common Stock	$5.00	J	3150000	Disposed	2016-09-30	Series A Common Stock (3150000)	Direct

Footnotes

F1: The Reporting Person transferred to the Issuer 75,771 shares Series A Common Stock of the Issuer and warrants to purchase 3,150,000 shares of Series A Common Stock of the Issuer in connection with a (a) the cross-licensing and sublicensing of certain patent rights and technology between the Issuer, the Reporting Person and another subsidiary of the Reporting Person, and (b) the transfer of shares of capital stock of certain subsidiaries of the Reporting Person from the Issuer to the Reporting Person. The shares of Series A Common Stock were valued at $3.07 per share, and the warrants were valued at $2,906,883, by the Reporting Person and the Issuer for purposes of the transaction.